Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4073-4085

  Chen, Hui Ming ^a   Ma, Ge ^a   Gildener Leapman, Neil ^b   Eisenstein, Samuel ^a   Coakley, Brian A ^a   Ozao, Junko ^a   Mandeli, John ^a   Divino, Celia ^a   Schwartz, Myron ^a   Sung, Max ^a   Ferris, Robert ^b   Kao, Johnny ^c   Wang, Lu Hai ^d   Pan, Ping Ying ^a   Ko, Eric C ^a,e,f   Chen, Shu Hsia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Good Samaritan Hospital Medical Center   (United States)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; BIOLOGICAL MARKER; CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD33 ANTIGEN; GAMMA INTERFERON; STAT3 PROTEIN; SUNITINIB; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER PROGNOSIS; CAUSE SPECIFIC SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; OLIGOMETASTASIS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; STEREOTACTIC BODY RADIATION THERAPY; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION; BONE MARROW CELL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOLOGY; DISEASE COURSE; FLOW CYTOMETRY; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; MONOCYTE; MONONUCLEAR CELL; NEOPLASMS; PHOSPHORYLATION; RADIOSURGERY; TREATMENT OUTCOME;

ANTIGENS, CD11B; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INDOLES; LEUKOCYTES, MONONUCLEAR; MONOCYTES; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASMS; PHOSPHORYLATION; PYRROLES; RADIOSURGERY; SIALIC ACID BINDING IG-LIKE LECTIN 3; STAT3 TRANSCRIPTION FACTOR; TREATMENT OUTCOME;

EID: 84942931851     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2742     Document Type: Article

References (53)

1. Tree AC, Khoo VS, Eeles R.A., Ahmed M., Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14: e28-37.
2. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012; 83: 878-86.
3. Seiwert TY, Salama JK, Vokes EE The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 2007; 4: 86-100.
4. Postow MA, Callahan MK, Barker C.A., Yamada Y., Yuan J, Kitano S, et al Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-31.
5. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007; 356:323-8.
6. Kleibeuker EA, Griffioen AW, Verheul H.M., Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 2012; 15: 173-82.
7. Kao J, Packer S, Vu H.L., Schwartz ME, Sung MW, Stock RG, et al Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009; 115: 3571-80.
8. Kao J, Chen CT, Tong C.C., Packer SH, Schwartz M, Chen SH, et al Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol 2014; 9: 145-53.
9. Tong CC, Ko EC, Sung M.W., Cesaretti JA, Stock RG, Packer SH, et al Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligome-tastases. PLoS ONE 2012; 7: e36979.
10. Ozao-Choy J., Ma G, Kao J., Wang GX, Meseck M, Sung M, et al The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-22.
11. Huang B, Pan PY, Li Q, Sato A.I., Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-31.
12. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11: 802-7.
13. Rogacev KS, Cremers B, Zawada A.M., Seiler S., Binder N, Ege P, et al CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-20.
14. Zawada AM, Rogacev KS, Rotter B, Winter P., Marell RR, Fliser D, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-61.
15. Ma G, Pan PY, Eisenstein S, Divino C.M., Lowell CA, Takai T, et al. Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity 2011; 34:385-95.
16. Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Chen HM, Meseck M, et al. Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res 2013; 73: 5003-15.
17. Vasquez-Dunddel D., Pan F, Zeng Q., Gorbounov M, Albesiano E, Fu J., et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013; 123: 1580-9.
18. Poschke I, Mougiakakos D, Hansson J., Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-45.
19. Zhang HP, Takayama K, Su B., Jiao XD, Li R, Wang JJ. Effect of sunitinib combined with ionizing radiation on endothelial cells. J Radiat Res 2011; 52: 1-8.
20. El Kaffas A., Al-Mahrouki A, Tran W.T., Giles A., Czarnota GJ. Sunitinib effects on the radiation response of endothelial and breast tumor cells. Microvasc Res 2014; 92: 1-9.
21. Dalhaug A, Haukland E, Nieder C. Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report). World J Surg Oncol 2010; 8: 36.
22. Brooks C, Sheu T, Bridges K., Mason K, Kuban D, Mathew P., et al. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 2012; 7: 154.
23. Diaz-Montero C.M., Salem ML, Nishimura M.I., Garrett-Mayer E, Cole DJ, Montero AJ Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59.
24. Zhang B, Wang Z, Wu L., Zhang M, Li W, Ding J., et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 2013; 8: e57114.
25. Castagna A, Polati R, Bossi A.M., Girelli D. Monocyte/macrophage proteomics: recent findings and biomedical applications. Expert Rev Proteomics 2012; 9: 201-15.
26. Wong KL, Yeap WH, Tai J.J., Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res 2012; 53: 41-57.
27. Belge KU, Dayyani F, Horelt A., Siedlar M, Frankenberger M, Frankenberger B, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-42.
28. Abeles RD, McPhail MJ, Sowter D, Antoniades C.G., Vergis N., Vijay GK, et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi)/CD16(neg) monocytes: expansion of CD14(hi)/CD16(pos) and contraction of CD14(lo)/CD16(pos) monocytes in acute liver failure. Cytometry A 2012; 81: 823-34.
29. Fujisawa T, Murase K, Kanoh H., Takemura M, Ohnishi H, Seishima M. Adsorptive depletion of CD14(+)CD16(+) proinflammatory monocyte phenotype in patients with generalized pustular psoriasis: clinical efficacy and effects on cytokines. Ther Apher Dial 2012; 16:436-44.
30. Zhang JY, Zou ZS, Huang A, Zhang Z., Fu JL, Xu XS, et al. Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS ONE 2011; 6: e17484.
31. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-92.
32. Finke J, Ko J, Rini B., Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11: 856-61.
33. Najjar YG, Finke JH Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013; 3: 49.
34. Kancha RK, Grundler R, Peschel C., Duyster J. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol 2007; 35: 1522-6.
35. Erdem L, Giovannetti E, Leon L.G., Honeywell R., Peters GJ. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem 2012; 12: 1649-59.
36. Pan PY, Wang GX, Yin B, Ozao J., Ku T, Divino CM, et al Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-28.
37. Noh J, Choi WS, Noh G, Lee JH Presence of Foxp3-expressing CD19(+) CD5(+) B cells in human peripheral blood mononuclear cells: human CD19(+)CD5(+)Foxp3(+) regulatory B cell (Breg). Immune Netw 2010; 10: 247-9.
38. Hua F, Ji L, Zhan Y., Li F, Zou S, Wang X., et al. Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia. J Clin Immunol 2012; 32: 1233-42.
39. de Koning J.P., Soede-Bobok AA, Ward A.C., Schelen AM, Antonissen C, van Leeuwen D, et al. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 2000; 19: 3290-8.
40. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cellsasregulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
41. Coccia EM, Del Russo N, Stellacci E, Testa U., Marziali G, Battistini A. STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. Int Immunol 1999; 11: 1075-83.
42. Kalliolias GD, Ivashkiv LB IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol 2008; 180:6325-33.
43. Rahimi AA, Gee K, Mishra S., Lim W, Kumar A. STAT-1 mediates the stimulatory effect of IL-10 on CD14 expression in human monocytic cells. J Immunol 2005; 174: 7823-32.
44. Golden EB, Pellicciotta I, Demaria S., Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2: 88.
45. Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015; 25: 11-7.
46. Ko JS, Zea AH, Rini B.I., Ireland JL, Elson P, Cohen P, et al Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57.
47. Walter S, Weinschenk T, Stenzl A., Zdrojowy R, Pluzanska A, Szczylik C., et al. Multipeptide immune responsetocancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-61.
48. Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 2014; 63: 1177-87.
49. Weide B, Martens A, Zelba H., Stutz C, Derhovanessian E, Di Giacomo AM, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1-or melan-A-specific T cells. Clin Cancer Res 2014; 20:1601-9.
50. Chen LJ, Zheng X, Shen Y.P., Zhu YB, Li Q, Chen J, et al Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother 2013; 62: 553-61.
51. Tosolini M, Kirilovsky A, Mlecnik B., Fredriksen T, Mauger S, Bindea G., et al. Clinical impact of different classes of infiltrating Tcytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-71.
52. Ladoire S, Arnould L, Mignot G., Apetoh L, Rebe C, Martin F., et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 2011; 105: 366-71.
53. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P., Montandon N, Leyvraz L, et al Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014; 63: 247-57.